ArticleThe Journal of experimental medicine2011
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
Article in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- The CD160-HVEM axis at the crossroads of tolerance and immunity: lessons from cancer for autoimmunity and transplantation.Frontiers in immunology · 2026Review
- MutantFrontiers in immunology · 2026Article
- Protein disulfide isomerase A1 as a novel redox sensor in VEGFR2 signaling and angiogenesis.Angiogenesis · 2023Article
- The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.Cancer immunology, immunotherapy : CII · 2022Article
- The Association Between Breast Cancer and Blood-Based Methylation ofFrontiers in genetics · 2022Article
- CD160 receptor in CLL: Current state and future avenues.Frontiers in immunology · 2022Review
- Nestin contributes to laser choroidal and retinal neovascularization.Molecular vision · 2022Article
- A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats.Scientific reports · 2020Article
- Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.Acta pharmaceutica Sinica. B · 2020Review
- Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.Frontiers in oncology · 2020Article
- A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.Oncotarget · 2019Article
- HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.Frontiers in immunology · 2018Article
- Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.Cancers · 2017Review
- MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.Nature communications · 2016Article
- Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells.BioMed research international · 2016Review
- CD160 isoforms and regulation of CD4 and CD8 T-cell responses.Journal of translational medicine · 2014Article
- CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.PLoS pathogens · 2014Article
- TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.The Journal of investigative dermatology · 2014Article
- Lymphotoxin network pathways shape the tumor microenvironment.Current opinion in immunology · 2013Review
- Profiling of genes associated with the murine model of oxygen-induced retinopathy.Molecular vision · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis plays an essential role in several diseases of the eye and in the growth of solid tumors, but existing antiangiogenic therapies have limited benefits in several cases. We report the antiangiogenic effects of a monoclonal antibody, CL1-R2, in several animal models of neovascularization. CL1-R2 recognizes human CD160, a membrane receptor which is conserved in various mammal species. We show that CD160 is expressed on the endothelial cells of newly formed blood vessels in human colon carcinoma and mouse B16 melanoma but not in vessels of healthy tissues. CL1-R2 reduced fibroblast growth factor 2-induced neovascularization in the rabbit cornea, in a mouse model of oxygen-induced retinopathy, and in a mouse Matrigel plug assay. Treatment of B16 melanoma-bearing mice with CL1-R2 combined with cyclophosphamide chemotherapy caused regression of the tumor vasculature and normalization of the remaining vessels as shown by Doppler ultrasonography, intravital microscopy, and histology. These studies validate CD160 as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.